Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial
A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa. For this open-label,...
Uloženo v:
| Vydáno v: | The Lancet (British edition) Ročník 386; číslo 9996; s. 857 - 866 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Elsevier Ltd
29.08.2015
Elsevier Limited |
| Témata: | |
| ISSN: | 0140-6736, 1474-547X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa.
For this open-label, cluster-randomised ring vaccination trial, suspected cases of Ebola virus disease in Basse-Guinée (Guinea, west Africa) were independently ascertained by Ebola response teams as part of a national surveillance system. After laboratory confirmation of a new case, clusters of all contacts and contacts of contacts were defined and randomly allocated 1:1 to immediate vaccination or delayed (21 days later) vaccination with rVSV-ZEBOV (one dose of 2 × 107 plaque-forming units, administered intramuscularly in the deltoid muscle). Adults (age ≥18 years) who were not pregnant or breastfeeding were eligible for vaccination. Block randomisation was used, with randomly varying blocks, stratified by location (urban vs rural) and size of rings (≤20 vs >20 individuals). The study is open label and masking of participants and field teams to the time of vaccination is not possible, but Ebola response teams and laboratory workers were unaware of allocation to immediate or delayed vaccination. Taking into account the incubation period of the virus of about 10 days, the prespecified primary outcome was laboratory-confirmed Ebola virus disease with onset of symptoms at least 10 days after randomisation. The primary analysis was per protocol and compared the incidence of Ebola virus disease in eligible and vaccinated individuals in immediate vaccination clusters with the incidence in eligible individuals in delayed vaccination clusters. This trial is registered with the Pan African Clinical Trials Registry, number PACTR201503001057193.
Between April 1, 2015, and July 20, 2015, 90 clusters, with a total population of 7651 people were included in the planned interim analysis. 48 of these clusters (4123 people) were randomly assigned to immediate vaccination with rVSV-ZEBOV, and 42 clusters (3528 people) were randomly assigned to delayed vaccination with rVSV-ZEBOV. In the immediate vaccination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after randomisation, whereas in the delayed vaccination group there were 16 cases of Ebola virus disease from seven clusters, showing a vaccine efficacy of 100% (95% CI 74·7–100·0; p=0·0036). No new cases of Ebola virus disease were diagnosed in vaccinees from the immediate or delayed groups from 6 days post-vaccination. At the cluster level, with the inclusion of all eligible adults, vaccine effectiveness was 75·1% (95% CI −7·1 to 94·2; p=0·1791), and 76·3% (95% CI −15·5 to 95·1; p=0·3351) with the inclusion of everyone (eligible or not eligible for vaccination). 43 serious adverse events were reported; one serious adverse event was judged to be causally related to vaccination (a febrile episode in a vaccinated participant, which resolved without sequelae). Assessment of serious adverse events is ongoing.
The results of this interim analysis indicate that rVSV-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease, and is most likely effective at the population level when delivered during an Ebola virus disease outbreak via a ring vaccination strategy.
WHO, with support from the Wellcome Trust (UK); Médecins Sans Frontières; the Norwegian Ministry of Foreign Affairs through the Research Council of Norway; and the Canadian Government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre, and Department of Foreign Affairs, Trade and Development. |
|---|---|
| AbstractList | Summary Background A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa. Methods For this open-label, cluster-randomised ring vaccination trial, suspected cases of Ebola virus disease in Basse-Guinée (Guinea, west Africa) were independently ascertained by Ebola response teams as part of a national surveillance system. After laboratory confirmation of a new case, clusters of all contacts and contacts of contacts were defined and randomly allocated 1:1 to immediate vaccination or delayed (21 days later) vaccination with rVSV-ZEBOV (one dose of 2 × 107 plaque-forming units, administered intramuscularly in the deltoid muscle). Adults (age ≥18 years) who were not pregnant or breastfeeding were eligible for vaccination. Block randomisation was used, with randomly varying blocks, stratified by location (urban vs rural) and size of rings (≤20 vs >20 individuals). The study is open label and masking of participants and field teams to the time of vaccination is not possible, but Ebola response teams and laboratory workers were unaware of allocation to immediate or delayed vaccination. Taking into account the incubation period of the virus of about 10 days, the prespecified primary outcome was laboratory-confirmed Ebola virus disease with onset of symptoms at least 10 days after randomisation. The primary analysis was per protocol and compared the incidence of Ebola virus disease in eligible and vaccinated individuals in immediate vaccination clusters with the incidence in eligible individuals in delayed vaccination clusters. This trial is registered with the Pan African Clinical Trials Registry, number PACTR201503001057193. Findings Between April 1, 2015, and July 20, 2015, 90 clusters, with a total population of 7651 people were included in the planned interim analysis. 48 of these clusters (4123 people) were randomly assigned to immediate vaccination with rVSV-ZEBOV, and 42 clusters (3528 people) were randomly assigned to delayed vaccination with rVSV-ZEBOV. In the immediate vaccination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after randomisation, whereas in the delayed vaccination group there were 16 cases of Ebola virus disease from seven clusters, showing a vaccine efficacy of 100% (95% CI 74·7–100·0; p=0·0036). No new cases of Ebola virus disease were diagnosed in vaccinees from the immediate or delayed groups from 6 days post-vaccination. At the cluster level, with the inclusion of all eligible adults, vaccine effectiveness was 75·1% (95% CI −7·1 to 94·2; p=0·1791), and 76·3% (95% CI −15·5 to 95·1; p=0·3351) with the inclusion of everyone (eligible or not eligible for vaccination). 43 serious adverse events were reported; one serious adverse event was judged to be causally related to vaccination (a febrile episode in a vaccinated participant, which resolved without sequelae). Assessment of serious adverse events is ongoing. Interpretation The results of this interim analysis indicate that rVSV-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease, and is most likely effective at the population level when delivered during an Ebola virus disease outbreak via a ring vaccination strategy. Funding WHO , with support from the Wellcome Trust (UK) ; Médecins Sans Frontières ; the Norwegian Ministry of Foreign Affairs through the Research Council of Norway; and the Canadian Government through the Public Health Agency of Canada, Canadian Institutes of Health Research , International Development Research Centre , and Department of Foreign Affairs, Trade and Development. Background A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa. Methods For this open-label, cluster-randomised ring vaccination trial, suspected cases of Ebola virus disease in Basse-Guinee (Guinea, west Africa) were independently ascertained by Ebola response teams as part of a national surveillance system. After laboratory confirmation of a new case, clusters of all contacts and contacts of contacts were defined and randomly allocated 1:1 to immediate vaccination or delayed (21 days later) vaccination with rVSV-ZEBOV (one dose of 2107 plaque-forming units, administered intramuscularly in the deltoid muscle). Adults (age greater than or equal to 18 years) who were not pregnant or breastfeeding were eligible for vaccination. Block randomisation was used, with randomly varying blocks, stratified by location (urban vs rural) and size of rings ( less than or equal to 20 vs >20 individuals). The study is open label and masking of participants and field teams to the time of vaccination is not possible, but Ebola response teams and laboratory workers were unaware of allocation to immediate or delayed vaccination. Taking into account the incubation period of the virus of about 10 days, the prespecified primary outcome was laboratory-confirmed Ebola virus disease with onset of symptoms at least 10 days after randomisation. The primary analysis was per protocol and compared the incidence of Ebola virus disease in eligible and vaccinated individuals in immediate vaccination clusters with the incidence in eligible individuals in delayed vaccination clusters. This trial is registered with the Pan African Clinical Trials Registry, number PACTR201503001057193. Findings Between April 1, 2015, and July 20, 2015, 90 clusters, with a total population of 7651 people were included in the planned interim analysis. 48 of these clusters (4123 people) were randomly assigned to immediate vaccination with rVSV-ZEBOV, and 42 clusters (3528 people) were randomly assigned to delayed vaccination with rVSV-ZEBOV. In the immediate vaccination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after randomisation, whereas in the delayed vaccination group there were 16 cases of Ebola virus disease from seven clusters, showing a vaccine efficacy of 100% (95% CI 74.7-100.0; p=0.0036). No new cases of Ebola virus disease were diagnosed in vaccinees from the immediate or delayed groups from 6 days post-vaccination. At the cluster level, with the inclusion of all eligible adults, vaccine effectiveness was 75.1% (95% CI -7.1 to 94.2; p=0.1791), and 76.3% (95% CI -15.5 to 95.1; p=0.3351) with the inclusion of everyone (eligible or not eligible for vaccination). 43 serious adverse events were reported; one serious adverse event was judged to be causally related to vaccination (a febrile episode in a vaccinated participant, which resolved without sequelae). Assessment of serious adverse events is ongoing. Interpretation The results of this interim analysis indicate that rVSV-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease, and is most likely effective at the population level when delivered during an Ebola virus disease outbreak via a ring vaccination strategy. Funding WHO, with support from the Wellcome Trust (UK); Medecins Sans Frontieres; the Norwegian Ministry of Foreign Affairs through the Research Council of Norway; and the Canadian Government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre, and Department of Foreign Affairs, Trade and Development. BACKGROUNDA recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa.METHODSFor this open-label, cluster-randomised ring vaccination trial, suspected cases of Ebola virus disease in Basse-Guinée (Guinea, west Africa) were independently ascertained by Ebola response teams as part of a national surveillance system. After laboratory confirmation of a new case, clusters of all contacts and contacts of contacts were defined and randomly allocated 1:1 to immediate vaccination or delayed (21 days later) vaccination with rVSV-ZEBOV (one dose of 2 × 10(7) plaque-forming units, administered intramuscularly in the deltoid muscle). Adults (age ≥18 years) who were not pregnant or breastfeeding were eligible for vaccination. Block randomisation was used, with randomly varying blocks, stratified by location (urban vs rural) and size of rings (≤20 vs >20 individuals). The study is open label and masking of participants and field teams to the time of vaccination is not possible, but Ebola response teams and laboratory workers were unaware of allocation to immediate or delayed vaccination. Taking into account the incubation period of the virus of about 10 days, the prespecified primary outcome was laboratory-confirmed Ebola virus disease with onset of symptoms at least 10 days after randomisation. The primary analysis was per protocol and compared the incidence of Ebola virus disease in eligible and vaccinated individuals in immediate vaccination clusters with the incidence in eligible individuals in delayed vaccination clusters. This trial is registered with the Pan African Clinical Trials Registry, number PACTR201503001057193.FINDINGSBetween April 1, 2015, and July 20, 2015, 90 clusters, with a total population of 7651 people were included in the planned interim analysis. 48 of these clusters (4123 people) were randomly assigned to immediate vaccination with rVSV-ZEBOV, and 42 clusters (3528 people) were randomly assigned to delayed vaccination with rVSV-ZEBOV. In the immediate vaccination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after randomisation, whereas in the delayed vaccination group there were 16 cases of Ebola virus disease from seven clusters, showing a vaccine efficacy of 100% (95% CI 74·7-100·0; p=0·0036). No new cases of Ebola virus disease were diagnosed in vaccinees from the immediate or delayed groups from 6 days post-vaccination. At the cluster level, with the inclusion of all eligible adults, vaccine effectiveness was 75·1% (95% CI -7·1 to 94·2; p=0·1791), and 76·3% (95% CI -15·5 to 95·1; p=0·3351) with the inclusion of everyone (eligible or not eligible for vaccination). 43 serious adverse events were reported; one serious adverse event was judged to be causally related to vaccination (a febrile episode in a vaccinated participant, which resolved without sequelae). Assessment of serious adverse events is ongoing.INTERPRETATIONThe results of this interim analysis indicate that rVSV-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease, and is most likely effective at the population level when delivered during an Ebola virus disease outbreak via a ring vaccination strategy.FUNDINGWHO, with support from the Wellcome Trust (UK); Médecins Sans Frontières; the Norwegian Ministry of Foreign Affairs through the Research Council of Norway; and the Canadian Government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre, and Department of Foreign Affairs, Trade and Development. A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa. For this open-label, cluster-randomised ring vaccination trial, suspected cases of Ebola virus disease in Basse-Guinée (Guinea, west Africa) were independently ascertained by Ebola response teams as part of a national surveillance system. After laboratory confirmation of a new case, clusters of all contacts and contacts of contacts were defined and randomly allocated 1:1 to immediate vaccination or delayed (21 days later) vaccination with rVSV-ZEBOV (one dose of 2 × 10(7) plaque-forming units, administered intramuscularly in the deltoid muscle). Adults (age ≥18 years) who were not pregnant or breastfeeding were eligible for vaccination. Block randomisation was used, with randomly varying blocks, stratified by location (urban vs rural) and size of rings (≤20 vs >20 individuals). The study is open label and masking of participants and field teams to the time of vaccination is not possible, but Ebola response teams and laboratory workers were unaware of allocation to immediate or delayed vaccination. Taking into account the incubation period of the virus of about 10 days, the prespecified primary outcome was laboratory-confirmed Ebola virus disease with onset of symptoms at least 10 days after randomisation. The primary analysis was per protocol and compared the incidence of Ebola virus disease in eligible and vaccinated individuals in immediate vaccination clusters with the incidence in eligible individuals in delayed vaccination clusters. This trial is registered with the Pan African Clinical Trials Registry, number PACTR201503001057193. Between April 1, 2015, and July 20, 2015, 90 clusters, with a total population of 7651 people were included in the planned interim analysis. 48 of these clusters (4123 people) were randomly assigned to immediate vaccination with rVSV-ZEBOV, and 42 clusters (3528 people) were randomly assigned to delayed vaccination with rVSV-ZEBOV. In the immediate vaccination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after randomisation, whereas in the delayed vaccination group there were 16 cases of Ebola virus disease from seven clusters, showing a vaccine efficacy of 100% (95% CI 74·7-100·0; p=0·0036). No new cases of Ebola virus disease were diagnosed in vaccinees from the immediate or delayed groups from 6 days post-vaccination. At the cluster level, with the inclusion of all eligible adults, vaccine effectiveness was 75·1% (95% CI -7·1 to 94·2; p=0·1791), and 76·3% (95% CI -15·5 to 95·1; p=0·3351) with the inclusion of everyone (eligible or not eligible for vaccination). 43 serious adverse events were reported; one serious adverse event was judged to be causally related to vaccination (a febrile episode in a vaccinated participant, which resolved without sequelae). Assessment of serious adverse events is ongoing. The results of this interim analysis indicate that rVSV-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease, and is most likely effective at the population level when delivered during an Ebola virus disease outbreak via a ring vaccination strategy. WHO, with support from the Wellcome Trust (UK); Médecins Sans Frontières; the Norwegian Ministry of Foreign Affairs through the Research Council of Norway; and the Canadian Government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre, and Department of Foreign Affairs, Trade and Development. A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa. Methods For this open-label, cluster-randomised ring vaccination trial, suspected cases of Ebola virus disease in Basse-Guinée (Guinea, west Africa) were independently ascertained by Ebola response teams as part of a national surveillance system. After laboratory confirmation of a new case, clusters of all contacts and contacts of contacts were defined and randomly allocated 1:1 to immediate vaccination or delayed (21 days later) vaccination with rVSV-ZEBOV (one dose of 2 x 107plaque-forming units, administered intramuscularly in the deltoid muscle). Adults (age >=18 years) who were not pregnant or breastfeeding were eligible for vaccination. Block randomisation was used, with randomly varying blocks, stratified by location (urbanvsrural) and size of rings (<=20vs>20 individuals). The study is open label and masking of participants and field teams to the time of vaccination is not possible, but Ebola response teams and laboratory workers were unaware of allocation to immediate or delayed vaccination. Taking into account the incubation period of the virus of about 10 days, the prespecified primary outcome was laboratory-confirmed Ebola virus disease with onset of symptoms at least 10 days after randomisation. The primary analysis was per protocol and compared the incidence of Ebola virus disease in eligible and vaccinated individuals in immediate vaccination clusters with the incidence in eligible individuals in delayed vaccination clusters. This trial is registered with the Pan African Clinical Trials Registry, number PACTR201503001057193. Findings Between April 1, 2015, and July 20, 2015, 90 clusters, with a total population of 7651 people were included in the planned interim analysis. 48 of these clusters (4123 people) were randomly assigned to immediate vaccination with rVSV-ZEBOV, and 42 clusters (3528 people) were randomly assigned to delayed vaccination with rVSV-ZEBOV. In the immediate vaccination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after randomisation, whereas in the delayed vaccination group there were 16 cases of Ebola virus disease from seven clusters, showing a vaccine efficacy of 100% (95% CI 74·7-100·0; p=0·0036). No new cases of Ebola virus disease were diagnosed in vaccinees from the immediate or delayed groups from 6 days post-vaccination. At the cluster level, with the inclusion of all eligible adults, vaccine effectiveness was 75·1% (95% CI -7·1 to 94·2; p=0·1791), and 76·3% (95% CI -15·5 to 95·1; p=0·3351) with the inclusion of everyone (eligible or not eligible for vaccination). 43 serious adverse events were reported; one serious adverse event was judged to be causally related to vaccination (a febrile episode in a vaccinated participant, which resolved without sequelae). Assessment of serious adverse events is ongoing. Interpretation The results of this interim analysis indicate that rVSV-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease, and is most likely effective at the population level when delivered during an Ebola virus disease outbreak via a ring vaccination strategy. Funding WHO, with support from the Wellcome Trust (UK); Médecins Sans Frontières; the Norwegian Ministry of Foreign Affairs through the Research Council of Norway; and the Canadian Government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre, and Department of Foreign Affairs, Trade and Development. A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa. For this open-label, cluster-randomised ring vaccination trial, suspected cases of Ebola virus disease in Basse-Guinée (Guinea, west Africa) were independently ascertained by Ebola response teams as part of a national surveillance system. After laboratory confirmation of a new case, clusters of all contacts and contacts of contacts were defined and randomly allocated 1:1 to immediate vaccination or delayed (21 days later) vaccination with rVSV-ZEBOV (one dose of 2 × 107 plaque-forming units, administered intramuscularly in the deltoid muscle). Adults (age ≥18 years) who were not pregnant or breastfeeding were eligible for vaccination. Block randomisation was used, with randomly varying blocks, stratified by location (urban vs rural) and size of rings (≤20 vs >20 individuals). The study is open label and masking of participants and field teams to the time of vaccination is not possible, but Ebola response teams and laboratory workers were unaware of allocation to immediate or delayed vaccination. Taking into account the incubation period of the virus of about 10 days, the prespecified primary outcome was laboratory-confirmed Ebola virus disease with onset of symptoms at least 10 days after randomisation. The primary analysis was per protocol and compared the incidence of Ebola virus disease in eligible and vaccinated individuals in immediate vaccination clusters with the incidence in eligible individuals in delayed vaccination clusters. This trial is registered with the Pan African Clinical Trials Registry, number PACTR201503001057193. Between April 1, 2015, and July 20, 2015, 90 clusters, with a total population of 7651 people were included in the planned interim analysis. 48 of these clusters (4123 people) were randomly assigned to immediate vaccination with rVSV-ZEBOV, and 42 clusters (3528 people) were randomly assigned to delayed vaccination with rVSV-ZEBOV. In the immediate vaccination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after randomisation, whereas in the delayed vaccination group there were 16 cases of Ebola virus disease from seven clusters, showing a vaccine efficacy of 100% (95% CI 74·7–100·0; p=0·0036). No new cases of Ebola virus disease were diagnosed in vaccinees from the immediate or delayed groups from 6 days post-vaccination. At the cluster level, with the inclusion of all eligible adults, vaccine effectiveness was 75·1% (95% CI −7·1 to 94·2; p=0·1791), and 76·3% (95% CI −15·5 to 95·1; p=0·3351) with the inclusion of everyone (eligible or not eligible for vaccination). 43 serious adverse events were reported; one serious adverse event was judged to be causally related to vaccination (a febrile episode in a vaccinated participant, which resolved without sequelae). Assessment of serious adverse events is ongoing. The results of this interim analysis indicate that rVSV-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease, and is most likely effective at the population level when delivered during an Ebola virus disease outbreak via a ring vaccination strategy. WHO, with support from the Wellcome Trust (UK); Médecins Sans Frontières; the Norwegian Ministry of Foreign Affairs through the Research Council of Norway; and the Canadian Government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre, and Department of Foreign Affairs, Trade and Development. |
| Author | Egger, Matthias Dean, Natalie E Draguez, Bertrand Henao-Restrepo, Ana Maria Trelle, Sven Gunther, Stephan Kéïta, Sakoba Kieny, Marie Paule Kondé, Mandy Kader Duraffour, Sophie Norheim, Gunnstein Levine, Myron M Grais, Rebecca Camacho, Anton Mandal, Sema Hossmann, Stefanie Longini, Ira M Kuisma, Eeva Røttingen, John-Arne Riveros, Ximena Soumah, Aboubacar Watson, Conall H Carroll, Miles W Vicari, Andrea S Edmunds, W John Kone, Souleymane Enwere, Godwin Doumbia, Moussa |
| Author_xml | – sequence: 1 givenname: Ana Maria surname: Henao-Restrepo fullname: Henao-Restrepo, Ana Maria organization: World Health Organization, Geneva, Switzerland – sequence: 2 givenname: Ira M surname: Longini fullname: Longini, Ira M organization: Department of Biostatistics, University of Florida, Gainesville, FL, USA – sequence: 3 givenname: Matthias surname: Egger fullname: Egger, Matthias organization: Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland – sequence: 4 givenname: Natalie E surname: Dean fullname: Dean, Natalie E organization: Department of Biostatistics, University of Florida, Gainesville, FL, USA – sequence: 5 givenname: W John surname: Edmunds fullname: Edmunds, W John organization: Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK – sequence: 6 givenname: Anton surname: Camacho fullname: Camacho, Anton organization: Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK – sequence: 7 givenname: Miles W surname: Carroll fullname: Carroll, Miles W organization: Public Health England, Porton Down, Wiltshire, UK – sequence: 8 givenname: Moussa surname: Doumbia fullname: Doumbia, Moussa organization: Centre pour Développement des Vaccins, Bamako, Mali – sequence: 9 givenname: Bertrand surname: Draguez fullname: Draguez, Bertrand organization: Médecins Sans Frontières, Brussels, Belgium – sequence: 10 givenname: Sophie surname: Duraffour fullname: Duraffour, Sophie organization: The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany – sequence: 11 givenname: Godwin surname: Enwere fullname: Enwere, Godwin organization: World Health Organization, Geneva, Switzerland – sequence: 12 givenname: Rebecca surname: Grais fullname: Grais, Rebecca organization: Epicentre, Paris, France – sequence: 13 givenname: Stephan surname: Gunther fullname: Gunther, Stephan organization: WHO Collaborating Centre for Arboviruses and Hemorrhagic Fever Reference and Research, Department of Virology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany – sequence: 14 givenname: Stefanie surname: Hossmann fullname: Hossmann, Stefanie organization: Clinical Trials Unit, University of Bern, Bern, Switzerland – sequence: 15 givenname: Mandy Kader surname: Kondé fullname: Kondé, Mandy Kader organization: CEFORPAG, Conakry, Guinea – sequence: 16 givenname: Souleymane surname: Kone fullname: Kone, Souleymane organization: World Health Organization, Geneva, Switzerland – sequence: 17 givenname: Eeva surname: Kuisma fullname: Kuisma, Eeva organization: Public Health England, Porton Down, Wiltshire, UK – sequence: 18 givenname: Myron M surname: Levine fullname: Levine, Myron M organization: Center for Vaccine Development, University of Maryland, Baltimore, MD, USA – sequence: 19 givenname: Sema surname: Mandal fullname: Mandal, Sema organization: Public Health England, London, UK – sequence: 20 givenname: Gunnstein surname: Norheim fullname: Norheim, Gunnstein organization: Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway – sequence: 21 givenname: Ximena surname: Riveros fullname: Riveros, Ximena organization: World Health Organization, Geneva, Switzerland – sequence: 22 givenname: Aboubacar surname: Soumah fullname: Soumah, Aboubacar organization: Epicentre, Paris, France – sequence: 23 givenname: Sven surname: Trelle fullname: Trelle, Sven organization: Clinical Trials Unit, University of Bern, Bern, Switzerland – sequence: 24 givenname: Andrea S surname: Vicari fullname: Vicari, Andrea S organization: World Health Organization, Geneva, Switzerland – sequence: 25 givenname: Conall H surname: Watson fullname: Watson, Conall H organization: Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK – sequence: 26 givenname: Sakoba surname: Kéïta fullname: Kéïta, Sakoba organization: Ebola Response, Ministry of Health, Conakry, Guinea – sequence: 27 givenname: Marie Paule surname: Kieny fullname: Kieny, Marie Paule email: kienym@who.int organization: World Health Organization, Geneva, Switzerland – sequence: 28 givenname: John-Arne surname: Røttingen fullname: Røttingen, John-Arne organization: Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26248676$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt9qFDEUhwep2D_6CErAm3oxmjMzycxYVKSsVSh4US3ehWzmpKZmkzXJLO4T-ZpmdluFBWmvEsJ3vpz8cg6LPecdFsVToC-BAn91QaGhJW9rfgzsBQeAtmQPigNo2qZkTfttrzj4i-wXhzFeU0obTtmjYr_iVdPxlh8Uv2daGyXVmkg3ENQaVTIrdBgj8TofknB5cVmu8rEPOJCVVMo4JPhrGTJj3BWZzb2VJI5BS4Xkyq6VXwaf0LjXxLiEwSxIZkebItHBL0j6juRszBZJwiTYOmUy3hFlx5hLypDb8QsT85UpGGkfFw-1tBGf3KxHxdcPsy-nH8vzz2efTt-fl4qzKpXzGhCwB4p0aPqeajoFo3Wdd5z1laZY14OsWV9jJ3VFGQIMPXBsm66r5vVRcbz15if8HDEmkZtQaK106McooK0q6KCu-nugtG8BeA8Zfb6DXvsxuPyQicq6rqVtpp7dUON8gYNY5uRkWIvb38rAyRZQwccYUAtl0ia3FKSxAqiYZkNsZkNMHy-Aic1sCJar2U717QV31b3b1mHOfWUwiKgMOoWDCXksxODNnYa3OwZljctjZ3_gGuO_LESsBN1KJgewjWESvPm_4B4N_AEuP_om |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1016_j_paed_2016_11_007 crossref_primary_10_1093_infdis_jiz241 crossref_primary_10_1016_j_vaccine_2015_10_130 crossref_primary_10_1080_09687599_2016_1145384 crossref_primary_10_3390_genes10030189 crossref_primary_10_1093_infdis_jix189 crossref_primary_10_3389_fimmu_2022_942897 crossref_primary_10_1016_S0001_4079_19_30572_2 crossref_primary_10_1038_524027a crossref_primary_10_1016_S1473_3099_23_00819_8 crossref_primary_10_1186_s13045_025_01694_2 crossref_primary_10_1038_s41577_020_00434_6 crossref_primary_10_1038_s41598_017_03910_7 crossref_primary_10_1016_j_clim_2016_10_016 crossref_primary_10_1016_j_virusres_2015_12_019 crossref_primary_10_1038_nri_2017_143 crossref_primary_10_1093_infdis_jix190 crossref_primary_10_1038_srep25856 crossref_primary_10_2217_fmb_2019_0237 crossref_primary_10_1016_j_antiviral_2018_04_020 crossref_primary_10_1093_infdis_jiz132 crossref_primary_10_1016_j_addr_2020_06_019 crossref_primary_10_1186_s12916_015_0477_2 crossref_primary_10_3389_fimmu_2023_1259197 crossref_primary_10_3390_vaccines10040533 crossref_primary_10_7717_peerj_1674 crossref_primary_10_1016_j_vaccine_2017_06_026 crossref_primary_10_3851_IMP3165 crossref_primary_10_1016_j_coviro_2016_03_003 crossref_primary_10_1016_j_coviro_2016_03_008 crossref_primary_10_1371_journal_pcbi_1013274 crossref_primary_10_1016_S0140_6736_17_31224_2 crossref_primary_10_1007_s13337_025_00940_y crossref_primary_10_1146_annurev_virology_092818_015708 crossref_primary_10_1007_s00018_016_2215_0 crossref_primary_10_1016_S1473_3099_15_00534_4 crossref_primary_10_1016_j_vaccine_2017_07_054 crossref_primary_10_1371_journal_pntd_0006628 crossref_primary_10_1038_nrd_2017_251 crossref_primary_10_1371_journal_pone_0202753 crossref_primary_10_1016_S0140_6736_16_32619_8 crossref_primary_10_1038_srep24782 crossref_primary_10_1080_14760584_2016_1178068 crossref_primary_10_1016_j_chom_2018_07_009 crossref_primary_10_1016_j_tim_2018_08_008 crossref_primary_10_1089_hs_2018_0092 crossref_primary_10_1186_s12985_019_1272_z crossref_primary_10_1186_s12992_017_0233_9 crossref_primary_10_1128_jvi_01627_23 crossref_primary_10_1016_j_jim_2019_03_008 crossref_primary_10_1038_s41467_025_61571_x crossref_primary_10_1002_sim_9972 crossref_primary_10_1016_S0140_6736_15_01244_1 crossref_primary_10_1016_j_vaccine_2021_08_094 crossref_primary_10_1016_j_ijpe_2021_108193 crossref_primary_10_1016_j_coi_2016_05_014 crossref_primary_10_1128_JVI_00520_20 crossref_primary_10_1189_jlb_4RI0316_099RR crossref_primary_10_1016_j_micinf_2018_04_005 crossref_primary_10_1038_srep27944 crossref_primary_10_1186_s12916_016_0678_3 crossref_primary_10_1371_journal_pntd_0005470 crossref_primary_10_1016_S1473_3099_15_00416_8 crossref_primary_10_1371_journal_pone_0192312 crossref_primary_10_1056_NEJMe1915350 crossref_primary_10_1093_oxfimm_iqab010 crossref_primary_10_3390_molecules23123310 crossref_primary_10_3389_fimmu_2023_1138961 crossref_primary_10_1038_srep21674 crossref_primary_10_1038_nri_2016_138 crossref_primary_10_1093_bja_aew068 crossref_primary_10_15585_mmwr_rr7001a1 crossref_primary_10_1016_j_coviro_2024_101408 crossref_primary_10_1080_14760584_2017_1394842 crossref_primary_10_1111_eva_12497 crossref_primary_10_1093_biostatistics_kxaa037 crossref_primary_10_1016_S0140_6736_16_32618_6 crossref_primary_10_1017_S143192762002262X crossref_primary_10_1093_jpids_piv086 crossref_primary_10_1126_science_aaf4561 crossref_primary_10_1016_S0140_6736_18_32205_0 crossref_primary_10_3390_vaccines11081317 crossref_primary_10_1038_s41598_018_29401_x crossref_primary_10_1136_medethics_2016_103843 crossref_primary_10_1007_s11262_017_1455_x crossref_primary_10_1371_journal_ppat_1006037 crossref_primary_10_1371_journal_ppat_1006397 crossref_primary_10_1097_IPC_0000000000000644 crossref_primary_10_1080_09581596_2019_1597966 crossref_primary_10_1016_j_actpha_2015_06_013 crossref_primary_10_1038_s41564_019_0453_2 crossref_primary_10_1056_NEJMoa1411627 crossref_primary_10_1093_cei_uxad003 crossref_primary_10_1099_jgv_0_001085 crossref_primary_10_1016_j_coviro_2017_12_003 crossref_primary_10_1016_j_cell_2015_10_027 crossref_primary_10_1016_S0140_6736_15_01243_X crossref_primary_10_1016_j_tmrv_2016_02_003 crossref_primary_10_3390_life11080734 crossref_primary_10_1007_s40124_016_0109_0 crossref_primary_10_1089_hum_2017_018 crossref_primary_10_7861_clinmedicine_19_2_140 crossref_primary_10_1016_S0140_6736_16_32617_4 crossref_primary_10_1038_s41598_017_11387_7 crossref_primary_10_1002_jmv_25615 crossref_primary_10_1016_j_vaccine_2015_12_075 crossref_primary_10_1093_bmb_ldw005 crossref_primary_10_1016_j_coi_2022_102210 crossref_primary_10_1080_22221751_2024_2432353 crossref_primary_10_1016_j_vaccine_2016_12_019 crossref_primary_10_1038_ncomms15327 crossref_primary_10_1002_hast_580 crossref_primary_10_1038_nm1215_1384 crossref_primary_10_1038_nm_4201 crossref_primary_10_1038_ni_3328 crossref_primary_10_1016_j_vaccine_2018_09_009 crossref_primary_10_1002_wnan_1383 crossref_primary_10_1038_nm1215_1380 crossref_primary_10_1371_journal_pntd_0011955 crossref_primary_10_1128_jvi_01166_21 crossref_primary_10_3389_fvets_2019_00016 crossref_primary_10_1038_srep33987 crossref_primary_10_1093_infdis_jiw496 crossref_primary_10_1016_j_cpem_2016_01_002 crossref_primary_10_3389_fmicb_2020_00304 crossref_primary_10_1016_j_jbiotec_2020_01_015 crossref_primary_10_1177_0020731415611644 crossref_primary_10_1016_j_vaccine_2022_08_061 crossref_primary_10_1093_infdis_jix336 crossref_primary_10_1080_14760584_2019_1698952 crossref_primary_10_1007_s40262_015_0364_1 crossref_primary_10_1128_microbiolspec_EI10_0022_2016 crossref_primary_10_1371_journal_pone_0166858 crossref_primary_10_1016_S1473_3099_19_30614_0 crossref_primary_10_1371_journal_ppat_1007564 crossref_primary_10_1007_s13311_016_0457_z crossref_primary_10_1093_infdis_jiy565 crossref_primary_10_1093_infdis_jiw145 crossref_primary_10_1016_j_vaccine_2024_05_079 crossref_primary_10_1371_journal_pone_0270968 crossref_primary_10_1371_journal_pone_0173148 crossref_primary_10_1371_journal_pmed_1001911 crossref_primary_10_2105_AJPH_2016_303311 crossref_primary_10_1177_1740774515619877 crossref_primary_10_1016_S1473_3099_21_00006_2 crossref_primary_10_1177_1740774515620612 crossref_primary_10_1177_1740774515620613 crossref_primary_10_1542_peds_2016_1891 crossref_primary_10_1080_14712598_2020_1787981 crossref_primary_10_3390_pharmaceutics15030947 crossref_primary_10_3390_vaccines9010059 crossref_primary_10_1038_s41392_021_00797_9 crossref_primary_10_3201_eid2202_151456 crossref_primary_10_1073_pnas_1806200115 crossref_primary_10_1016_j_antiviral_2017_12_007 crossref_primary_10_3389_fimmu_2019_00372 crossref_primary_10_1093_cid_ciaa1290 crossref_primary_10_1093_infdis_jiy698 crossref_primary_10_1093_ije_dyv307 crossref_primary_10_4103_0974_777X_170495 crossref_primary_10_3390_vaccines6010016 crossref_primary_10_1371_journal_pntd_0006349 crossref_primary_10_1016_S1473_3099_15_00291_1 crossref_primary_10_1089_vim_2017_0122 crossref_primary_10_3201_eid2506_181620 crossref_primary_10_1126_science_aai8126 crossref_primary_10_3390_vaccines8020241 crossref_primary_10_1186_s40794_020_00129_9 crossref_primary_10_1016_S0140_6736_15_00946_0 crossref_primary_10_1016_j_clp_2021_03_006 crossref_primary_10_1016_j_vaccine_2017_01_068 crossref_primary_10_3390_v10080439 crossref_primary_10_1128_JVI_02154_16 crossref_primary_10_1136_bmjgh_2022_010984 crossref_primary_10_1016_S1473_3099_20_30736_2 crossref_primary_10_1146_annurev_micro_090817_062414 crossref_primary_10_1371_journal_pone_0254044 crossref_primary_10_1016_S0140_6736_17_30131_9 crossref_primary_10_4236_health_2022_141011 crossref_primary_10_1177_1740774515621870 crossref_primary_10_1016_j_coi_2021_03_008 crossref_primary_10_1016_j_immuni_2017_02_005 crossref_primary_10_1038_s41572_020_0147_3 crossref_primary_10_1172_JCI89857 crossref_primary_10_1111_mam_12082 crossref_primary_10_1016_j_coviro_2018_01_010 crossref_primary_10_4997_jrcpe_2018_316 crossref_primary_10_1016_S1473_3099_20_30515_6 crossref_primary_10_1038_srep45886 crossref_primary_10_1073_pnas_2118895119 crossref_primary_10_1007_s10393_016_1100_5 crossref_primary_10_1016_S0140_6736_19_31211_5 crossref_primary_10_1016_j_smim_2018_07_003 crossref_primary_10_1016_S1473_3099_17_30234_7 crossref_primary_10_1093_cid_cix907 crossref_primary_10_3390_microorganisms8101473 crossref_primary_10_3389_fimmu_2020_599568 crossref_primary_10_1126_scitranslmed_abg6128 crossref_primary_10_1136_bmjopen_2015_009346 crossref_primary_10_1002_nop2_258 crossref_primary_10_1111_ane_13417 crossref_primary_10_1038_s41426_018_0031_3 crossref_primary_10_1128_JVI_01703_18 crossref_primary_10_1007_s11017_017_9402_3 crossref_primary_10_1128_JVI_01967_19 crossref_primary_10_3389_fmed_2021_651658 crossref_primary_10_3390_v11010079 crossref_primary_10_1007_s40264_020_01002_6 crossref_primary_10_1136_medethics_2015_102657 crossref_primary_10_1371_journal_ppat_1005221 crossref_primary_10_3389_fimmu_2017_00252 crossref_primary_10_1016_j_omto_2018_05_001 crossref_primary_10_1080_17425247_2024_2445675 crossref_primary_10_1186_s12992_020_00548_5 crossref_primary_10_1177_2168479016680253 crossref_primary_10_3389_fmicb_2017_01571 crossref_primary_10_3390_biomedicines5010008 crossref_primary_10_1016_S0140_6736_18_30559_2 crossref_primary_10_1371_journal_pone_0140651 crossref_primary_10_1016_j_coviro_2022_101210 crossref_primary_10_1038_s41598_018_31003_6 crossref_primary_10_1586_14760584_2016_1170597 crossref_primary_10_1186_s12967_016_1084_5 crossref_primary_10_3389_fpls_2016_00054 crossref_primary_10_3390_vaccines9101187 crossref_primary_10_1371_journal_pntd_0008206 crossref_primary_10_1128_microbiolspec_MTBP_0003_2016 crossref_primary_10_1016_S0140_6736_15_00002_1 crossref_primary_10_1016_S1473_3099_24_00419_5 crossref_primary_10_1093_tbm_ibaf025 crossref_primary_10_1093_infdis_jiy020 crossref_primary_10_1128_JVI_00048_20 crossref_primary_10_1177_1740774516673355 crossref_primary_10_3389_fimmu_2020_586595 crossref_primary_10_1186_s12916_017_0985_3 crossref_primary_10_3390_vaccines10081263 crossref_primary_10_1038_nature_2015_18107 crossref_primary_10_1055_a_2292_4455 crossref_primary_10_1080_14760584_2018_1527692 crossref_primary_10_1038_s41467_021_21630_5 crossref_primary_10_1016_S1473_3099_19_30207_5 crossref_primary_10_1056_NEJMe1512928 crossref_primary_10_1016_j_jmb_2016_07_019 crossref_primary_10_1016_j_vaccine_2017_03_068 crossref_primary_10_1016_S1473_3099_17_30575_3 crossref_primary_10_1038_s41417_022_00436_7 crossref_primary_10_1111_1468_0009_12186 crossref_primary_10_1016_j_cct_2015_12_008 crossref_primary_10_1093_infdis_jiad280 crossref_primary_10_1016_j_vaccine_2017_02_015 crossref_primary_10_1038_npjvaccines_2016_2 crossref_primary_10_1208_s12248_022_00764_4 crossref_primary_10_1016_j_vaccine_2018_04_016 crossref_primary_10_1016_S1473_3099_15_00486_7 crossref_primary_10_1038_s41467_021_21411_0 crossref_primary_10_1016_j_socscimed_2015_11_017 crossref_primary_10_1016_S0140_6736_16_30127_1 crossref_primary_10_1016_j_antiviral_2015_09_015 crossref_primary_10_1002_adhm_201600750 crossref_primary_10_1016_S1473_3099_18_30649_2 crossref_primary_10_15252_embr_201846675 crossref_primary_10_1371_journal_pmed_1001994 crossref_primary_10_1056_NEJMp1613577 crossref_primary_10_1016_j_vaccine_2017_10_111 crossref_primary_10_1371_journal_pntd_0005093 crossref_primary_10_1016_j_epidem_2021_100506 crossref_primary_10_1038_s41586_020_03146_y crossref_primary_10_1080_14760584_2017_1309977 crossref_primary_10_1016_j_jcv_2016_11_005 crossref_primary_10_1186_s12916_017_0911_8 crossref_primary_10_1016_j_vaccine_2017_04_085 crossref_primary_10_1038_nrmicro3540 crossref_primary_10_1128_microbiolspec_EI10_0011_2016 crossref_primary_10_1038_s41467_022_29015_y crossref_primary_10_1371_journal_pntd_0005087 crossref_primary_10_1186_s13054_016_1325_2 crossref_primary_10_1016_j_micinf_2018_01_005 crossref_primary_10_1016_S1473_3099_17_30541_8 crossref_primary_10_1136_bmjgh_2016_000180 crossref_primary_10_1186_s40249_016_0197_7 crossref_primary_10_1016_j_chom_2020_01_001 crossref_primary_10_2105_AJPH_2018_304344 crossref_primary_10_1016_j_imlet_2019_03_008 crossref_primary_10_1016_j_cmi_2024_11_027 crossref_primary_10_3390_ijerph16112020 crossref_primary_10_1186_s12916_015_0524_z crossref_primary_10_1016_j_xphs_2016_07_020 crossref_primary_10_1146_annurev_med_052915_015604 crossref_primary_10_1093_jtm_taab086 crossref_primary_10_1038_s41541_019_0104_x crossref_primary_10_1186_s12985_024_02585_7 crossref_primary_10_1080_14760584_2016_1187566 crossref_primary_10_1002_phar_2068 crossref_primary_10_1007_s40475_019_00195_w crossref_primary_10_1186_s12910_016_0094_4 crossref_primary_10_1126_science_aad8521 crossref_primary_10_1038_s41541_020_0179_4 crossref_primary_10_1093_infdis_jix657 crossref_primary_10_1016_j_vaccine_2017_08_001 crossref_primary_10_1016_S0140_6736_16_00686_3 crossref_primary_10_1128_microbiolspec_EI10_0014_2016 crossref_primary_10_3390_vaccines6030043 crossref_primary_10_1177_0956462417703572 crossref_primary_10_1093_cid_ciz1165 crossref_primary_10_3390_v15030698 crossref_primary_10_1080_13543784_2016_1240785 crossref_primary_10_3201_eid2603_191018 crossref_primary_10_1016_S1473_3099_17_30313_4 crossref_primary_10_1080_14712598_2018_1404572 crossref_primary_10_1093_infdis_jiw218 crossref_primary_10_1093_infdis_jiy639 crossref_primary_10_1016_S1473_3099_22_00584_9 crossref_primary_10_1056_NEJMoa1414216 crossref_primary_10_1371_journal_pmed_1002402 crossref_primary_10_1016_j_coviro_2021_10_007 crossref_primary_10_1016_S0140_6736_16_32621_6 crossref_primary_10_1128_JVI_00592_21 crossref_primary_10_1016_S1473_3099_15_00465_X crossref_primary_10_1126_scitranslmed_aaj1701 crossref_primary_10_3390_microorganisms7100402 crossref_primary_10_1002_wnan_1403 crossref_primary_10_1146_annurev_virology_110615_040056 crossref_primary_10_1186_s12978_017_0429_8 crossref_primary_10_1093_infdis_jiw231 crossref_primary_10_1093_infdis_jiw352 crossref_primary_10_1080_20502877_2017_1387386 crossref_primary_10_1371_journal_pntd_0004802 crossref_primary_10_1016_j_jinf_2016_04_016 crossref_primary_10_1002_gch2_1011 crossref_primary_10_3389_fendo_2019_00081 crossref_primary_10_1111_lest_12144 crossref_primary_10_1371_journal_pmed_1002535 crossref_primary_10_1002_biuz_201510578 crossref_primary_10_3201_eid2813_212123 crossref_primary_10_1016_j_ijid_2016_07_013 crossref_primary_10_1371_journal_pone_0160410 crossref_primary_10_1080_07391102_2024_2305314 crossref_primary_10_1038_s41598_017_19041_y crossref_primary_10_1093_ofid_ofw031 crossref_primary_10_1093_cid_ciw793 crossref_primary_10_1016_S0163_4453_17_30205_0 crossref_primary_10_2217_fvl_15_74 crossref_primary_10_1016_j_vaccine_2017_05_097 crossref_primary_10_1177_1740774515617754 crossref_primary_10_1371_journal_ppat_1006932 crossref_primary_10_1016_j_vaccine_2017_03_019 crossref_primary_10_3201_eid2508_190281 crossref_primary_10_1016_S1473_3099_15_00362_X crossref_primary_10_1016_j_chom_2020_07_018 crossref_primary_10_1016_j_vaccine_2019_01_050 crossref_primary_10_1016_j_coviro_2019_07_006 crossref_primary_10_1080_14760584_2022_2126357 crossref_primary_10_1111_nyas_13355 crossref_primary_10_1038_s41598_017_07246_0 crossref_primary_10_7717_peerj_5888 crossref_primary_10_1371_journal_pntd_0004866 crossref_primary_10_1016_j_vaccine_2016_10_004 crossref_primary_10_1128_CVI_00298_16 crossref_primary_10_1080_19466315_2021_1939774 crossref_primary_10_1128_JVI_01190_17 crossref_primary_10_1016_S0140_6736_23_02193_1 crossref_primary_10_2105_AJPH_2015_302996 crossref_primary_10_1038_nmicrobiol_2016_128 crossref_primary_10_1038_s41598_018_29135_w crossref_primary_10_1056_NEJMoa1502924 crossref_primary_10_3390_v12111324 crossref_primary_10_1016_j_vaccine_2019_09_094 crossref_primary_10_1371_journal_pntd_0006919 crossref_primary_10_1038_srep23803 crossref_primary_10_1128_JVI_00941_17 crossref_primary_10_12688_f1000research_16989_1 crossref_primary_10_1007_s40265_017_0830_1 crossref_primary_10_1186_s41018_018_0039_2 crossref_primary_10_1016_j_vaccine_2017_08_058 crossref_primary_10_1177_1740774515621013 crossref_primary_10_3201_eid2201_151410 crossref_primary_10_1016_j_coviro_2017_03_008 crossref_primary_10_3390_vaccines8040779 crossref_primary_10_3390_v13020317 crossref_primary_10_3390_ijms21145130 crossref_primary_10_1038_s41433_020_01376_y crossref_primary_10_1016_j_puhe_2016_11_008 crossref_primary_10_1093_epirev_mxac003 crossref_primary_10_1111_1758_5899_12306 crossref_primary_10_1093_cid_ciy527 crossref_primary_10_1016_j_bmc_2016_08_065 crossref_primary_10_1128_CVI_00263_17 crossref_primary_10_1002_rmv_1917 crossref_primary_10_1038_mto_2016_21 crossref_primary_10_1016_j_ebiom_2019_09_055 crossref_primary_10_1016_j_jaut_2019_102375 crossref_primary_10_1080_26939169_2022_2074584 crossref_primary_10_1016_j_jcrc_2017_11_002 crossref_primary_10_1038_s41467_019_12499_6 crossref_primary_10_1073_pnas_1817329116 crossref_primary_10_3390_v14030579 crossref_primary_10_1007_s40259_018_0329_7 crossref_primary_10_1016_j_jcrc_2017_11_006 crossref_primary_10_1056_NEJMoa1614067 crossref_primary_10_1126_science_350_6257_170_b crossref_primary_10_1080_09687637_2016_1187113 crossref_primary_10_1038_s41598_017_01032_8 crossref_primary_10_1016_j_antiviral_2019_104567 crossref_primary_10_1093_cid_ciw114 crossref_primary_10_1186_s12887_017_0786_z crossref_primary_10_1002_psp4_12510 crossref_primary_10_1128_AAC_00530_20 crossref_primary_10_1056_NEJMsr2105280 crossref_primary_10_3389_fimmu_2023_1060481 crossref_primary_10_1093_aje_kwz090 crossref_primary_10_1128_JVI_00322_16 crossref_primary_10_1016_S1473_3099_15_00375_8 crossref_primary_10_1016_j_clp_2020_08_005 crossref_primary_10_1056_NEJMoa1904387 crossref_primary_10_1016_S0140_6736_16_31599_9 crossref_primary_10_1371_journal_pmed_1002227 crossref_primary_10_1016_j_vaccine_2016_06_071 crossref_primary_10_1371_journal_pmed_1002120 crossref_primary_10_1016_j_vaccine_2021_10_071 crossref_primary_10_1089_hs_2016_0002 crossref_primary_10_1097_MS9_0000000000002213 crossref_primary_10_1016_j_vaccine_2022_11_036 crossref_primary_10_1038_nbt1015_1011 crossref_primary_10_1590_1806_9282_62_05_458 crossref_primary_10_1038_nmicrobiol_2016_157 crossref_primary_10_1097_QCO_0000000000000462 crossref_primary_10_1080_14760584_2016_1184575 crossref_primary_10_1177_17407745211073594 crossref_primary_10_1016_j_compbiolchem_2017_11_006 crossref_primary_10_1016_j_epidem_2017_02_009 crossref_primary_10_1038_nrd_2015_35 crossref_primary_10_1038_s41467_018_05276_4 crossref_primary_10_1097_ICU_0000000000000313 crossref_primary_10_1177_1740774516679666 crossref_primary_10_1371_journal_pntd_0007814 crossref_primary_10_3390_v11040326 crossref_primary_10_1038_s41598_023_48397_7 crossref_primary_10_1007_s00103_018_2757_4 crossref_primary_10_1080_1062936X_2019_1573377 crossref_primary_10_1186_s12879_022_07723_6 crossref_primary_10_1038_nmicrobiol_2016_164 crossref_primary_10_1093_cid_ciw256 crossref_primary_10_1016_j_jfma_2023_06_001 crossref_primary_10_1097_ICU_0000000000000683 crossref_primary_10_1093_ije_dyw034 crossref_primary_10_1002_sim_10030 crossref_primary_10_1016_j_coi_2015_07_009 crossref_primary_10_1371_journal_pone_0137964 crossref_primary_10_1146_annurev_med_051215_030919 crossref_primary_10_1016_S0140_6736_15_00951_4 crossref_primary_10_1080_14760584_2020_1738225 crossref_primary_10_1177_17407745221110880 crossref_primary_10_15585_mmwr_mm6435a6 crossref_primary_10_29333_ejgm_9694 crossref_primary_10_3390_vaccines12020210 crossref_primary_10_1016_S1473_3099_16_30516_3 crossref_primary_10_3390_v13071397 crossref_primary_10_1080_07391102_2024_2446673 crossref_primary_10_1126_scitranslmed_aad3106 crossref_primary_10_1136_medethics_2016_103474 crossref_primary_10_1016_j_puhe_2015_11_005 crossref_primary_10_1093_infdis_jiv532 crossref_primary_10_1371_journal_pone_0179559 crossref_primary_10_1016_j_micpath_2019_05_010 crossref_primary_10_1016_j_vaccine_2016_04_047 crossref_primary_10_1016_j_imu_2018_07_004 crossref_primary_10_1073_pnas_1518587113 crossref_primary_10_1186_s13756_016_0112_9 crossref_primary_10_3390_v11121149 crossref_primary_10_1186_s13063_021_05134_7 crossref_primary_10_1136_medethics_2015_103292 crossref_primary_10_1136_jrnms_105_113 crossref_primary_10_1371_journal_pone_0250435 crossref_primary_10_1038_s41591_021_01302_z crossref_primary_10_1177_1740774515616944 crossref_primary_10_1146_annurev_pathol_052016_100506 crossref_primary_10_1126_scitranslmed_aat0360 crossref_primary_10_3390_vaccines12080828 crossref_primary_10_1111_bjd_14157 crossref_primary_10_1099_jgv_0_000286 crossref_primary_10_1098_rsos_171591 crossref_primary_10_1515_cclm_2016_0456 |
| Cites_doi | 10.1093/infdis/jir349 10.2307/2530245 10.1038/nm.2447 10.1016/S0140-6736(15)60553-0 10.1056/NEJMc1415318 10.1128/JVI.00561-09 10.1056/NEJMp1412166 10.1136/bmj.327.7418.785 10.1001/jama.1995.03530180050029 10.1056/NEJMoa1411100 |
| ContentType | Journal Article |
| Copyright | 2015 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Copyright © 2015 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited Aug 29, 2015 |
| Copyright_xml | – notice: 2015 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. – notice: World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. – notice: Copyright © 2015 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited Aug 29, 2015 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 |
| DOI | 10.1016/S0140-6736(15)61117-5 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts ProQuest Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni Edition) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional ProQuest Biological Science Collection Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database Medical Database Psychology Database ProQuest Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1474-547X |
| EndPage | 866 |
| ExternalDocumentID | 3792607781 26248676 10_1016_S0140_6736_15_61117_5 S0140673615611175 1_s2_0_S0140673615611175 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Guinea Africa |
| GeographicLocations_xml | – name: Guinea – name: Africa |
| GrantInformation | WHO, with support from the Wellcome Trust (UK); Médecins Sans Frontières; the Norwegian Ministry of Foreign Affairs through the Research Council of Norway; and the Canadian Government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre, and Department of Foreign Affairs, Trade and Development. |
| GrantInformation_xml | – fundername: WHO funderid: http://dx.doi.org/10.13039/100004423 – fundername: Médecins Sans Frontières funderid: http://dx.doi.org/10.13039/100008196 – fundername: Canadian Institutes of Health Research funderid: http://dx.doi.org/10.13039/501100000024 – fundername: International Development Research Centre funderid: http://dx.doi.org/10.13039/501100000193 – fundername: Department of Foreign Affairs, Trade and Development – fundername: Wellcome Trust (UK) funderid: http://dx.doi.org/10.13039/100004440 – fundername: Norwegian Ministry of Foreign Affairs funderid: http://dx.doi.org/10.13039/100007842 – fundername: Canadian Government – fundername: Canadian Institutes of Health Research – fundername: Wellcome Trust |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L M41 MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 9DU AAYXX ADXHL AFFHD AGQPQ AIGII CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c652t-b31e1e910e0d4990f01117ff30f06592f0e33da3593e8af205e11d916e74882b3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 587 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000360290000029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0140-6736 |
| IngestDate | Sun Nov 09 11:39:41 EST 2025 Sun Sep 28 06:35:44 EDT 2025 Sat Nov 29 15:04:36 EST 2025 Mon Jul 21 05:39:43 EDT 2025 Tue Nov 18 21:19:38 EST 2025 Sat Nov 29 07:23:56 EST 2025 Fri Feb 23 02:30:18 EST 2024 Sun Feb 23 10:18:50 EST 2025 Tue Oct 14 19:34:27 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9996 |
| Language | English |
| License | Copyright © 2015 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c652t-b31e1e910e0d4990f01117ff30f06592f0e33da3593e8af205e11d916e74882b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | http://www.thelancet.com/article/S0140673615611175/pdf |
| PMID | 26248676 |
| PQID | 1708138707 |
| PQPubID | 40246 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_1722181329 proquest_miscellaneous_1709711691 proquest_journals_1708138707 pubmed_primary_26248676 crossref_citationtrail_10_1016_S0140_6736_15_61117_5 crossref_primary_10_1016_S0140_6736_15_61117_5 elsevier_sciencedirect_doi_10_1016_S0140_6736_15_61117_5 elsevier_clinicalkeyesjournals_1_s2_0_S0140673615611175 elsevier_clinicalkey_doi_10_1016_S0140_6736_15_61117_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-08-29 |
| PublicationDateYYYYMMDD | 2015-08-29 |
| PublicationDate_xml | – month: 08 year: 2015 text: 2015-08-29 day: 29 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2015 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Sullivan, Hensley, Asiedu (bib2) 2011; 17 Hayes, Moulton (bib15) 2008 Agua-Agum, Ariyarajah, Blake (bib24) 2015; 372 Donner, Klar (bib16) 2000 Halloran, Longini, Struchiner (bib18) Puffer, Torgerson, Watson (bib21) 2003; 327 bib12 bib13 Ledgerwood, DeZure, Stanley (bib8) 2014 Rampling, Ewer, Bowyer (bib9) 2015 Fenner, Henderson, Arita, Ladnyi (bib11) Aalen, Borgan, Gjessing (bib19) Schulz (bib22) 1995; 274 Geisbert, Geisbert, Leung (bib4) 2009; 83 Zhu, Hou, Li (bib5) 2015; 385 (bib23) 2014; 371 (bib14) 2014 bib25 Kanapathipillai, Henao Restrepo, Fast (bib1) 2014; 371 Regules, Beigel, Paolino (bib6) 2015 O'Brien, Fleming (bib17) 1979; 35 (bib20) 2008 Geisbert, Feldmann (bib3) 2011; 204 Agnandji, Huttner, Zinser (bib7) 2015 (bib10) 2015; 351 Sullivan (10.1016/S0140-6736(15)61117-5_bib2) 2011; 17 Aalen (10.1016/S0140-6736(15)61117-5_bib19) (10.1016/S0140-6736(15)61117-5_bib10) 2015; 351 Halloran (10.1016/S0140-6736(15)61117-5_bib18) Schulz (10.1016/S0140-6736(15)61117-5_bib22) 1995; 274 Kanapathipillai (10.1016/S0140-6736(15)61117-5_bib1) 2014; 371 Hayes (10.1016/S0140-6736(15)61117-5_bib15) 2008 Regules (10.1016/S0140-6736(15)61117-5_bib6) 2015 (10.1016/S0140-6736(15)61117-5_bib23) 2014; 371 Geisbert (10.1016/S0140-6736(15)61117-5_bib3) 2011; 204 Agnandji (10.1016/S0140-6736(15)61117-5_bib7) 2015 Agua-Agum (10.1016/S0140-6736(15)61117-5_bib24) 2015; 372 Ledgerwood (10.1016/S0140-6736(15)61117-5_bib8) 2014 Fenner (10.1016/S0140-6736(15)61117-5_bib11) Donner (10.1016/S0140-6736(15)61117-5_bib16) 2000 Geisbert (10.1016/S0140-6736(15)61117-5_bib4) 2009; 83 Rampling (10.1016/S0140-6736(15)61117-5_bib9) 2015 O'Brien (10.1016/S0140-6736(15)61117-5_bib17) 1979; 35 Puffer (10.1016/S0140-6736(15)61117-5_bib21) 2003; 327 Zhu (10.1016/S0140-6736(15)61117-5_bib5) 2015; 385 (10.1016/S0140-6736(15)61117-5_bib20) 2008 26738715 - Lancet. 2015 Dec 19;386(10012):2478-80 27115974 - Lancet. 2016 Apr 9;387(10027):1509-10 27115973 - Lancet. 2016 Apr 9;387(10027):1509 26335862 - Lancet. 2015 Aug 29;386(9996):831-3 26738714 - Lancet. 2015 Dec 19;386(10012):2478 26738716 - Lancet. 2015 Dec 19;386(10012):2480 |
| References_xml | – volume: 372 start-page: 1274 year: 2015 end-page: 1277 ident: bib24 article-title: Ebola virus disease among children in West Africa publication-title: N Engl J Med – ident: bib13 article-title: Laboratory guidance for the diagnosis of Ebola virus disease. Interim recommendations – volume: 17 start-page: 1128 year: 2011 end-page: 1131 ident: bib2 article-title: CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates publication-title: Nat Med – year: 2015 ident: bib9 article-title: A monovalent chimpanzee adenovirus Ebola vaccine—preliminary report publication-title: N Engl J Med – volume: 351 start-page: h3740 year: 2015 ident: bib10 article-title: The ring vaccination trial: a novel cluster randomized controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola publication-title: BMJ – ident: bib25 article-title: Situation reports on Ebola response roadmap – ident: bib18 article-title: Design and analysis of vaccine studies – volume: 371 start-page: 1481 year: 2014 end-page: 1495 ident: bib23 article-title: Ebola virus disease in west Africa—the first 9 months of the epidemic and forward projections publication-title: N Engl J Med – year: 2014 ident: bib14 article-title: Case definition recommendations for Ebola or Marburg virus disease – volume: 327 start-page: 785 year: 2003 end-page: 789 ident: bib21 article-title: Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals publication-title: BMJ – year: 2008 ident: bib15 publication-title: Cluster randomised trials – year: 2015 ident: bib6 article-title: A recombinant vesicular stomatitis virus Ebola vaccine—preliminary report publication-title: N Engl J Med – ident: bib12 article-title: Contact tracing during an outbreak of Ebola virus disease – year: 2000 ident: bib16 publication-title: Design and analysis of cluster randomization trials in health research – ident: bib11 article-title: Smallpox and its eradication – volume: 204 start-page: S1075 year: 2011 end-page: S1081 ident: bib3 article-title: Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections publication-title: J Infect Dis – year: 2008 ident: bib20 publication-title: R: a language and environment for statistical computing – year: 2015 ident: bib7 article-title: Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report publication-title: N Engl J Med – volume: 35 start-page: 549 year: 1979 end-page: 556 ident: bib17 article-title: A multiple testing procedure for clinical trials publication-title: Biometrics – volume: 385 start-page: 2272 year: 2015 end-page: 2279 ident: bib5 article-title: Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial publication-title: Lancet – volume: 274 start-page: 1456 year: 1995 end-page: 1458 ident: bib22 article-title: Subverting randomization in controlled trials publication-title: JAMA – volume: 371 start-page: 2249 year: 2014 end-page: 2251 ident: bib1 article-title: Ebola vaccine—an urgent international priority publication-title: N Engl J Med – ident: bib19 article-title: Survival and event history analysis—a process point of view – volume: 83 start-page: 7296 year: 2009 end-page: 7304 ident: bib4 article-title: Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus publication-title: J Virol – year: 2014 ident: bib8 article-title: Chimpanzee adenovirus vector Ebola vaccine—preliminary report publication-title: N Engl J Med – ident: 10.1016/S0140-6736(15)61117-5_bib19 – volume: 204 start-page: S1075 issue: suppl year: 2011 ident: 10.1016/S0140-6736(15)61117-5_bib3 article-title: Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections publication-title: J Infect Dis doi: 10.1093/infdis/jir349 – year: 2014 ident: 10.1016/S0140-6736(15)61117-5_bib8 article-title: Chimpanzee adenovirus vector Ebola vaccine—preliminary report publication-title: N Engl J Med – ident: 10.1016/S0140-6736(15)61117-5_bib11 – volume: 35 start-page: 549 year: 1979 ident: 10.1016/S0140-6736(15)61117-5_bib17 article-title: A multiple testing procedure for clinical trials publication-title: Biometrics doi: 10.2307/2530245 – ident: 10.1016/S0140-6736(15)61117-5_bib18 – year: 2008 ident: 10.1016/S0140-6736(15)61117-5_bib20 – year: 2015 ident: 10.1016/S0140-6736(15)61117-5_bib7 article-title: Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report publication-title: N Engl J Med – volume: 17 start-page: 1128 year: 2011 ident: 10.1016/S0140-6736(15)61117-5_bib2 article-title: CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates publication-title: Nat Med doi: 10.1038/nm.2447 – volume: 385 start-page: 2272 year: 2015 ident: 10.1016/S0140-6736(15)61117-5_bib5 article-title: Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)60553-0 – volume: 372 start-page: 1274 year: 2015 ident: 10.1016/S0140-6736(15)61117-5_bib24 article-title: Ebola virus disease among children in West Africa publication-title: N Engl J Med doi: 10.1056/NEJMc1415318 – volume: 351 start-page: h3740 year: 2015 ident: 10.1016/S0140-6736(15)61117-5_bib10 article-title: The ring vaccination trial: a novel cluster randomized controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola publication-title: BMJ – year: 2015 ident: 10.1016/S0140-6736(15)61117-5_bib6 article-title: A recombinant vesicular stomatitis virus Ebola vaccine—preliminary report publication-title: N Engl J Med – volume: 83 start-page: 7296 year: 2009 ident: 10.1016/S0140-6736(15)61117-5_bib4 article-title: Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus publication-title: J Virol doi: 10.1128/JVI.00561-09 – year: 2000 ident: 10.1016/S0140-6736(15)61117-5_bib16 – volume: 371 start-page: 2249 year: 2014 ident: 10.1016/S0140-6736(15)61117-5_bib1 article-title: Ebola vaccine—an urgent international priority publication-title: N Engl J Med doi: 10.1056/NEJMp1412166 – year: 2008 ident: 10.1016/S0140-6736(15)61117-5_bib15 – year: 2015 ident: 10.1016/S0140-6736(15)61117-5_bib9 article-title: A monovalent chimpanzee adenovirus Ebola vaccine—preliminary report publication-title: N Engl J Med – volume: 327 start-page: 785 year: 2003 ident: 10.1016/S0140-6736(15)61117-5_bib21 article-title: Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals publication-title: BMJ doi: 10.1136/bmj.327.7418.785 – volume: 274 start-page: 1456 year: 1995 ident: 10.1016/S0140-6736(15)61117-5_bib22 article-title: Subverting randomization in controlled trials publication-title: JAMA doi: 10.1001/jama.1995.03530180050029 – volume: 371 start-page: 1481 year: 2014 ident: 10.1016/S0140-6736(15)61117-5_bib23 article-title: Ebola virus disease in west Africa—the first 9 months of the epidemic and forward projections publication-title: N Engl J Med doi: 10.1056/NEJMoa1411100 – reference: 27115973 - Lancet. 2016 Apr 9;387(10027):1509 – reference: 26738716 - Lancet. 2015 Dec 19;386(10012):2480 – reference: 27115974 - Lancet. 2016 Apr 9;387(10027):1509-10 – reference: 26738714 - Lancet. 2015 Dec 19;386(10012):2478 – reference: 26738715 - Lancet. 2015 Dec 19;386(10012):2478-80 – reference: 26335862 - Lancet. 2015 Aug 29;386(9996):831-3 |
| SSID | ssj0004605 |
| Score | 2.6542828 |
| Snippet | A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising... Summary Background A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus... BACKGROUNDA recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a... Background A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 857 |
| SubjectTerms | Adult Breast feeding Clinical trials Ebola Vaccines Ebola virus Ebolavirus - immunology Female Genetic Vectors Glycoproteins Guinea - epidemiology Hemorrhagic Fever, Ebola - epidemiology Hemorrhagic Fever, Ebola - prevention & control Humans Immunization Incidence Internal Medicine Kaplan-Meier Estimate Male Membrane Glycoproteins - metabolism Middle Aged Public health Vaccination - methods Vaccines Vesiculovirus - metabolism Young Adult |
| Title | Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673615611175 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673615611175 https://dx.doi.org/10.1016/S0140-6736(15)61117-5 https://www.ncbi.nlm.nih.gov/pubmed/26248676 https://www.proquest.com/docview/1708138707 https://www.proquest.com/docview/1709711691 https://www.proquest.com/docview/1722181329 |
| Volume | 386 |
| WOSCitedRecordID | wos000360290000029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYhhAS4mN8FUZlJB7gIVts13HDC4Kpg5eWahvV3iI3tqdKJRlNU7G_iH-TO8fNXroNiZdTm_rsqLncl8-_I-TdNNaxs0ZG4CyYqGf4NNJW2ig1UikIH1LOct9sQo1G_bOzdBwSblUoq1zrRK-oTZljjvyAKTBeAqRLfbr4FWHXKNxdDS00tsgOoiQIX7o33nQu0pe4X53gOThpL75n8kMCb7yK5HW26Trf09ugo0f_e_ePycPgfdLPjbg8IXdssUvuDcP--i550GTxaHM46Sn5M0CECZ1fUl0Y2tR-BPVISwcX6WJyMolWPvVvDV3pHCei9ndTX1uc08EUgmda1Qunc0vP55d56bEhZsVHilgVi9lPCmPr-bKieNaFgkdKv9Ywi6aYcwxzegGi-bxGYIcIDKwpQUJhSd925Bn5cTQ4PfwWhdYOUZ5IvoymgllmwVWxsYGYK3bY8l45J-ATbvS62AphtJCpsH3teCwtYwZcWatA4_CpeE62i7KwLwm1iXYQVslYuLSHWDqOGWakcS43EC3KDumtH2qWB9xzbL8xzzYUuDGZeVnIgG2_ZbtogD9uY0jWEpOtT7WCHs7ANN3GqDYx2ipokypjWcWzuOFGZoi5kRU4-y1ncJgaR-hfFt1bC2p2tU4rpR3ytv0ZniZuIunClrUfkyqGEEs3jeHoOQqedsiL5oVp_0OecAR5TF7dfAOvyX1wTSVm73m6R7aXi9q-IXfz1XJWLbpkSx1PkJ4pT_tA-4esS3a-DEbjY_g2jBt6ipQPPf3u6bjrlcRfmuVfhg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQICEuIxbYYCRQIIHs9ipkwYJIQQbm7ZWSCvT3owb21OlkoymKfQX8cZv5Bznspdu42UPvFWpjx055_LZ50bIi1GgA2eNZAAWDOsaMWLaSssSI-MYjg-J4KlvNhEPBr3Dw-TLCvnT5MJgWGWjE72iNnmKd-QbPAbjFQJ3xe-PfzDsGoXe1aaFRsUWu3bxE45sxbudT_B9XwqxtTn8uM3qrgIsjaSYsVHILbdgJW1gAO4HDrutx86F8At9jC6wYWh0KJPQ9rQTgbScG0BRNgZmF6MQ5r1ELmNdPQwh7AfDZXmYPqT-JGNoY799-IrL1xEuyeRptvA0rOtt3tat_223bpObNbqmHypxuENWbLZGrvbr-IE1cqO6paRV8tVd8nsTK2jodEF1ZmgV21Krf5o7eEinB_sHbO5dG9bQuU5xImp_VfHD2RHdHOUTTYty6nRq6dFkkea-9sU4e0uxFsd0_J3C2HIyKyjm8lBA3PRzCbNoineq9ZxeQGg6KbFwBQMAYXKQQFjSt1W5R75eyLbdJ6tZntmHhNpIOzg2yiB0SRdrBTluuJHGudTAaVh2SLdhIpXWdd2xvchELQng41J53lNA9qYlO64Km5xHEDUcqpqsXbAzCkzveYTxMkJb1NqyUFwVQgUVNRJz6UmBstdS1oCwAnr_suh6IxjqZJ1WKjrkefs3fE10kunM5qUfk8QcS0idNUYgMg5F0iEPKgFt91BEAotYRo_OfoFn5Nr2sL-n9nYGu4_JdYDhEj0VIlknq7NpaZ-QK-l8Ni6mT72KoeTbRUvpXxX2r9k |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQBMS4jJuhQFGAgkeTGO7ThokhNDWwjSYJo1NezOuL1OlkoymKfQX8R_4dRw7l710Gy974K1K_dmRc47PZ_tcEHoxilTkrBEEyIIhPcNGRFlhSWpEksD2IWVUh2ITye5u_-go3VtBf5pYGO9W2ayJYaE2ufZn5F2agPHiIF1J19VuEXtbw_cnP4ivIOVvWptyGpWI7NjFT9i-Fe-2t-Bbv2RsOPi6-YnUFQaIjgWbkRGnllqwmDYyQP0j5yuvJ85x-OXvG11kOTeKi5TbvnIsEpZSA4zKJiD4bMSh3yvoasJBin2U-iZdFpMZ3OtPo4e6--3DV1S8jv2QRJxlF8_ivcH-DW_9zzN3G92sWTf-UKnJHbRis3W09qX2K1hHN6rTS1wFZd1Fvwc-s4bSC6wygyufl9os4NzBQzw93D8k83DlYQ2eK-07wvZX5VecHePBKJ8oXJRTp7TFx5OFzkNOjHH2FvscHdPxdwxty8mswD7GBwMTxx9L6EVhf9Za9xkUB-tJ6RNaECAWJgfNhCFDuZV76OBSpu0-Ws3yzD5E2MbKwXZSRNylPZ9DyFFDjTDOaQO7ZNFBvUagpK7zvfuyIxO5xLGPChnkUALsTQs7qRKeXASIG2mVTTQv2B8JJvkiYLIMaIt6FS0klQWTUYX2YCoCFJD9FlkTxYoA_sugG42SyNNxWg3poOft3_A1_eWZymxehjZpQn1qqfPaMM-YOUs76EGlrO0cspj55Jbxo_Nf4BlaA-WUn7d3dx6j68DOhb_AYOkGWp1NS_sEXdPz2biYPg2rDUbfLltJ_wLTD7hX |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+effectiveness+of+an+rVSV-vectored+vaccine+expressing+Ebola+surface+glycoprotein%3A+interim+results+from+the+Guinea+ring+vaccination+cluster-randomised+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Henao-Restrepo%2C+Ana+Maria&rft.au=Longini%2C+Ira+M&rft.au=Egger%2C+Matthias&rft.au=Dean%2C+Natalie+E&rft.date=2015-08-29&rft.pub=Elsevier+Limited&rft.issn=0140-6736&rft.eissn=1474-547X&rft.volume=386&rft.issue=9996&rft.spage=857&rft_id=info:doi/10.1016%2FS0140-6736%2815%2961117-5&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3792607781 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673615X0002X%2Fcov150h.gif |